Remove Clinical Research Remove Pharmacokinetics Remove Therapies
article thumbnail

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

Drug Target Review

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. Difficult-to-treat and rare, complicated cancers remain a perplexing challenge for IO researchers. Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy.

article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

We also leverage existing clinical gene expression data from different subsets of molecularly profiled cancer patients, who differ in a certain aspect of disease or response to a particular therapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Informed Design of Bioanalytical PCR Assay Testing Parameters

PPD

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.

article thumbnail

Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)

Alta Sciences

The trial was performed at Altasciences’ clinical facility in Montréal. The Phase I trial was performed to evaluate safety, tolerability, and pharmacokinetics in a group of 80 healthy participants in a two-part, double-blind, placebo-controlled study. We are proud to support Ischemix in advancing this vital new therapy.”

Trials 40
article thumbnail

4 Unique Challenges of Oncology Trials

Advarra

Innovation Organizations conducting oncology clinical trials face challenges distinct from the rest of the research community. Often, medical innovations are first explored in oncology research (e.g., cell and gene therapies), with other therapeutic areas then pushing it further.

Trials 52
article thumbnail

Women in STEM with Cristina de Min

Drug Target Review

In reality, our deep understanding of disease pathology and patient needs is instrumental in shaping both basic and clinical research into viable treatments. Could you share an example of a specific project or research that you have worked on and the impact it has had in your field?

article thumbnail

Four Pain Models Altasciences Uses to Assess Treatments During Clinical Trials

Alta Sciences

As such, we wanted to share some of the methods our experts use to test and evaluate pain for both research, and treatment efficacy. This should help to demonstrate the elusive and somewhat nebulous nature of how we not only determine what pain is, but also how we can measure pain in clinical research. Click to learn more!